rethinkTHC Search
Menu
Study breakdown

Vaporized CBD produces much higher blood levels than oral CBD, and pure CBD does not convert to THC in the body

Randomized Controlled TrialModerate evidence
The takeaway

Vaporized CBD reached peak blood concentrations 8-12 times higher than oral CBD at the same 100 mg dose, and neither route produced detectable THC or its metabolites.

CBD users, clinicians, pharmacologists, and anyone concerned about CBD and drug testing.

Vaporized CBD peak: 171 ng/mL vs. oral: 14 ng/mL

What the researchers found

Mean peak CBD blood concentration was 171.1 ng/mL for vaporized CBD-dominant cannabis, 104.6 ng/mL for vaporized pure CBD, and only 13.7 ng/mL for oral CBD. Among oral formulations, Epidiolex produced the highest peak (20.5 ng/mL) vs. capsule (17.8 ng/mL) and syrup (2.8 ng/mL). Pure CBD by either route did not produce detectable THC or THC-COOH in blood.

Why it matters

Massive differences in bioavailability between oral and vaporized CBD have direct implications for dosing, product selection, and drug testing. The confirmation that pure CBD does not convert to THC addresses a common concern.

The numbers in context

Peak CBD: vaporized cannabis 171.1 ng/mL (range 40-665), vaporized pure CBD 104.6 ng/mL (range 19-312), oral CBD 13.7 ng/mL (range 0-50). THC detected in 12/18 after vaporized CBD-dominant cannabis but in 0/18 after pure CBD products.

How the study worked

Within-subject, double-blind, double-dummy, placebo-controlled study in 18 adults. Each participant received 100 mg CBD via oral, vaporized, and vaporized CBD-dominant cannabis (10.5% CBD/0.39% THC) routes, plus placebo. Blood and oral fluid were collected for 57-58 hours post-dose.

What this study cannot tell us

Small sample size (n=18). Single-dose study. Limited to three oral formulations. Fasting condition only tested in 6 participants. May not reflect real-world use patterns with repeated dosing.

How to read the evidence

Well-designed within-subject RCT with multiple comparisons, limited by small sample size.

When this study was published

Published in 2022.

The bigger picture

These pharmacokinetic differences explain why vaporized and oral CBD may produce different clinical effects and why research findings from one route may not apply to another. The absence of THC conversion is reassuring for workplace drug testing.

Questions still open

  • Do the higher blood levels from vaporization translate to greater therapeutic effects? Would repeated dosing change the pharmacokinetic profile? Should CBD dosing recommendations differ by route?

Common questions

Will taking CBD cause a positive drug test for THC?
In this study, pure CBD products (both oral and vaporized) did not produce detectable THC or its metabolite THC-COOH in blood. However, vaporized CBD-dominant cannabis containing 0.39% THC did produce detectable THC in 12 of 18 participants.
Why does vaporized CBD produce higher blood levels than oral CBD?
Inhaled CBD enters the bloodstream directly through the lungs, bypassing the digestive system and liver where oral CBD is extensively broken down before reaching circulation (first-pass metabolism).

Read the original research

Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.

Journal of analytical toxicology, 46(6), 583-591

Citation

Bergeria, Cecilia L; Spindle, Tory R; Cone, Edward J; Sholler, Dennis; Goffi, Elia; Mitchell, John M; Winecker, Ruth E; Bigelow, George E; Flegel, Ronald; Vandrey, Ryan. (2022). Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.. Journal of analytical toxicology, 46(6), 583-591. https://doi.org/10.1093/jat/bkab124

Explore the wider topic